Interpares Biomedicine is Drug Discovery in United States that focus on operator business. Founded in 2015. They cover business area such as operator, molecular diagnostic company, clinically actionable test, immunotherapy decision, oncology, personalized medicine solution, guidance, patient, metastatic solid tumor, essential information, drug developer, clinical oncologist, healthcare payer, new immunotherapy option, cancer treatment.
2015
( 9 years old in 2024 )
Operator
-
17003 Madres De Avila
Tampa, FL 33613
United States
Private
operatormolecular diagnostic companyclinically actionable testimmunotherapy decisiononcologypersonalized medicine solutionguidancepatientmetastatic solid tumoressential informationdrug developerclinical oncologisthealthcare payernew immunotherapy optioncancer treatment
* We use standard office opening hours in near Interpares Biomedicine's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Interpares Biomedicine is Drug Discovery business from United States that founded in 2015 (9 years old in 2024), Interpares Biomedicine business is focusing on Operator.
Interpares Biomedicine headquarter office and corporate office address is located in 17003 Madres De Avila Tampa, FL 33613 United States.
Interpares Biomedicine was founded in United States.
In 2024, Interpares Biomedicine is currently focus on operator sector.
Above is snippet of Google Trends for "operator" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Interpares Biomedicine, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
